Top Page
MedPlus Health Services Ltd.
(MEDPLUS)
MedPlus Health Services Ltd. (MEDPLUS) vs. iShares MSCI India ETF (INDA)
MedPlus Health Services Ltd. Business Overview & Revenue Model
MedPlus Health Services Ltd. Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.90B | 61.36B | 56.25B | 45.58B | 37.79B | 30.69B |
| Gross Profit | 15.44B | 14.70B | 12.14B | 9.82B | 7.85B | 6.38B |
| EBITDA | 3.56B | 3.24B | 2.08B | 1.41B | 1.87B | 1.52B |
| Net Income | 1.78B | 1.50B | 654.73M | 497.63M | 958.02M | 638.58M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 33.60B | 30.05B | 27.97B | 25.94B | 15.66B |
| Cash, Cash Equivalents and Short-Term Investments | 3.67B | 4.40B | 1.65B | 2.89B | 6.58B | 1.49B |
| Total Debt | 0.00 | 11.20B | 10.10B | 9.05B | 8.15B | 5.90B |
| Total Liabilities | -17.40B | 16.20B | 14.27B | 13.06B | 11.77B | 8.35B |
| Stockholders Equity | 17.40B | 17.41B | 15.78B | 14.91B | 14.18B | 7.31B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.95B | 593.38M | -785.95M | 521.68M | -513.67M |
| Operating Cash Flow | 0.00 | 5.54B | 1.44B | 904.10M | 1.70B | 28.91M |
| Investing Cash Flow | 0.00 | -3.32B | -827.99M | 4.29B | -7.03B | -345.49M |
| Financing Cash Flow | 0.00 | -2.28B | -1.98B | -1.70B | 4.40B | -56.26M |
MedPlus Health Services Ltd. Technical Analysis
MedPlus Health Services Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹103.11B | 64.65 | ― | 0.20% | 16.71% | 13.92% | |
67 Neutral | ₹81.18B | 423.34 | ― | ― | 17.58% | -38.20% | |
66 Neutral | ₹234.38B | 44.12 | ― | 0.89% | 10.80% | 32.79% | |
62 Neutral | ₹101.72B | 49.01 | ― | ― | 4.94% | 94.22% | |
61 Neutral | ₹98.65B | 58.60 | ― | 0.21% | 15.41% | 5.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹18.68B | -16.38 | ― | 0.08% | -2.81% | -444.69% |
MedPlus Health Services Ltd. Corporate Events
MedPlus Health Services Limited has made available the audio recording of its earnings call held on February 2, 2026, with analysts and institutional investors to discuss the company’s financial results for the quarter ended December 31, 2025. The recording can be accessed via a link on the company’s website and will also be hosted on the websites of BSE and the National Stock Exchange of India, enhancing transparency and accessibility of its financial disclosures for stakeholders.
MedPlus Health Services Ltd. has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a three-day suspension order for the drug license of one pharmacy store located at Durga Nagar Colony, Lingojiguda Village in Telangana, issued by the Assistant Director, Drugs Control Administration, Ranga Reddy district. The suspension, imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and related rules, is expected to result in a potential revenue loss of Rs 2.94 lakh, suggesting a limited financial impact at the group level but highlighting ongoing regulatory scrutiny that could influence operational compliance and oversight practices across its wider store network.
MedPlus Health Services Limited has issued a revised intimation regarding its earnings call for the quarter ended December 31, 2025, scheduled on February 2, 2026, after discovering that the earlier joining link shared with analysts and institutional investors was incorrect. The company has now provided an updated access link and detailed dial-in information, including international toll-free numbers, and noted that the corrected information is also available on its own website as well as on the BSE and NSE platforms, ensuring stakeholders have accurate details to participate in the call and mitigating any potential disruption to its investor communications.
MedPlus Health Services’ subsidiary Optival Health Solutions has received two separate orders from state Drugs Control Administration authorities suspending the drug licences of individual stores in Karwar, Karnataka and Uppal Prashanti Nagar, Telangana for two days each, citing violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and associated Rules. The company estimates a combined potential revenue loss of approximately Rs 2.79 lakh from these short-term suspensions, which affect only the specified outlets and are not expected to materially disrupt overall operations, but underscore ongoing regulatory scrutiny of compliance standards in the organized retail pharmacy sector.
MedPlus Health Services Ltd. has disclosed that its subsidiary Optival Health Solutions Private Limited has received six suspension orders affecting the drug licences of pharmacy stores in Karnataka and Telangana. Authorities in Bangalore, Nalgonda and Patancheruvu ordered temporary suspensions ranging from one to four days at specific outlets, citing violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and corresponding rules, leading to an estimated aggregate potential revenue loss of a few lakh rupees; while the financial impact is limited, the regulatory action underscores ongoing compliance scrutiny in the pharmaceutical retail sector and could prompt tighter operational controls at impacted locations.
MedPlus Health Services Ltd. has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension of the drug license for one of its retail pharmacy stores located on S Rammurthy Road in Virajpet, Karnataka, following an order from the Assistant Director, Drugs Control Administration, Madikeri Circle, under Rule 65 of the Drugs and Cosmetics Act, 1940 and associated Rules. The company estimates a potential revenue loss of approximately Rs 0.74 lakh from this temporary suspension, indicating that the operational and financial impact is limited and localized to a single outlet, with no broader disruption to MedPlus’s overall retail network or core business activities communicated at this time.
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received a one-day suspension order of the drug license for a retail store located on KC Rani Road in Gadag, Karnataka, issued by the Assistant Director of the state Drugs Control Administration. The suspension, imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and corresponding rules, is expected to result in an estimated potential revenue loss of about Rs 0.23 lakh, suggesting only a minimal financial and operational impact on the company’s overall business and stakeholders.
Agilemed Investments Private Limited, a promoter entity of MedPlus Health Services Limited, has released a pledge on 4,171,970 equity shares of the company. The disclosure, made under Regulation 31 of SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, 2011, signals a reduction in encumbrances on promoter-held shares, which may be viewed positively by investors as it can indicate improved financial flexibility and a stronger governance position for the listed pharmacy chain.
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders affecting drug licenses for retail pharmacy stores in Telangana and Maharashtra. The Jawahar Nagar store in Telangana faces a three-day license suspension ordered by the Assistant Director of the Drugs Control Administration, while the Radha Nagar-Kalyan store in Maharashtra faces a seven-day suspension ordered by the Food and Drug Administration, Mumbai; together, the suspensions are expected to result in a potential revenue loss of about Rs 5.54 lakh but are not indicated to materially disrupt the company’s overall operations.
MedPlus Health Services Ltd. has disclosed that its subsidiary Optival Health Solutions Private Limited has received three suspension orders for drug licenses covering three stores in Karnataka, located at Jayanagar 9th Block, T R Nagar, and Shiggon Haveri. The suspensions, issued by Assistant Directors of the Drugs Control Administration in Bangalore Circle-3 and Haveri Circle under Rule 65 of the Drugs and Cosmetics Act, 1940 and corresponding Rules, each apply for a three-day period and are linked to alleged violations of those provisions. The company estimates a combined potential revenue loss of roughly Rs 3.24 lakh from the temporary shutdowns, indicating a limited financial impact relative to overall operations, but highlighting ongoing regulatory scrutiny over compliance in its retail pharmacy network.
MedPlus Health Services Limited has disclosed that its promoter entity, Agilemed Investments Private Limited, has created a pledge over 48,51,066 equity shares of the company in compliance with Regulation 31 of SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, 2011. The move, formally notified to BSE and NSE, represents an encumbrance on a portion of the promoter’s holdings and is significant for investors tracking promoter share pledging activity, as it may influence perceptions of the company’s capital structure and promoter financing position, though no change in control or ownership has been indicated.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received three suspension orders for the Drug License of a store in Maharashtra. The suspensions, issued by the Food & Drug Administration in Amravati and Nagpur, are expected to result in a potential revenue loss of approximately Rs 10.17 lacs. This development may impact the company’s financial operations and highlights regulatory challenges in maintaining compliance with the Drugs and Cosmetics Act.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license at a store in Telangana. This suspension, issued by the Drugs Control Administration, is expected to result in a potential revenue loss of approximately Rs 0.87 lacs, highlighting a minor operational setback for the company.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license at one of its stores in Telangana. This suspension, issued by the Assistant Director of Drugs Control Administration, is due to violations under the Drugs and Cosmetics Act, 1940, and is expected to result in a potential revenue loss of approximately Rs 1.43 lacs, impacting the company’s financial operations.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a one-day suspension order for a drug license at a store located in Alnavara, Karnataka. This suspension, issued under the Drugs and Cosmetics Act, 1940, and related rules, is expected to result in a potential revenue loss of approximately Rs 0.33 Lacs, impacting the company’s financial operations.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at three of its stores located in Karnataka and Telangana. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 2.88 lacs. This development may impact the company’s short-term financial operations, but the overall implications for its market positioning remain to be seen.